LIFE TECHNOLOGIES GmbH
LIFE TECHNOLOGIES GmbH
5 Projects, page 1 of 1
Open Access Mandate for Publications assignment_turned_in Project2009 - 2012Partners:LUMC, UCL, Newcastle University, University of Ferrara, University of Rome Tor Vergata +10 partnersLUMC,UCL,Newcastle University,University of Ferrara,University of Rome Tor Vergata,ARIADNE,UNIMI,UNIPD,ACIES Consulting Group,Ariadne,KTH,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,LIFE TECHNOLOGIES GmbH,AMU,StCFunder: European Commission Project Code: 241665more_vert assignment_turned_in Project2008 - 2012Partners:COMPREHENSIVE BIOMARKER CENTER GMBH, Oxford Nanopore Technologies (United Kingdom), Lund University, Genewave (France), MPG +15 partnersCOMPREHENSIVE BIOMARKER CENTER GMBH,Oxford Nanopore Technologies (United Kingdom),Lund University,Genewave (France),MPG,Uppsala University,UOXF,FlexGen,GU,NAVINCI DIAGNOSTICS AB,CEA,CAU,TU Delft,PHILIPS ELECTRONICS NEDERLAND B.V.,University of Leicester,DTU,LIFE TECHNOLOGIES GmbH,University of Southampton,FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA,PHOTONIS FRANCE SASFunder: European Commission Project Code: 201418more_vert Open Access Mandate for Publications assignment_turned_in Project2010 - 2013Partners:CEA, EMBL, CAU, LUMC, FUNDACIO CENTRE DE REGULACIO GENOMICA +12 partnersCEA,EMBL,CAU,LUMC,FUNDACIO CENTRE DE REGULACIO GENOMICA,Uppsala University,LIFE TECHNOLOGIES GmbH,Helmholtz Zentrum München,JHU,USC,INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,ILLUMINA CAMBRIDGE LTD,STICHTING RADBOUD UNIVERSITEIT,GRL,FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA,MPG,UNIGEFunder: European Commission Project Code: 261123more_vert assignment_turned_in Project2012 - 2015Partners:Imperial, PHILIPS IBERICA, UMA, CORETHERAPIX, CNRS +7 partnersImperial,PHILIPS IBERICA,UMA,CORETHERAPIX,CNRS,Takara Bio Europe AB,Charité - University Medicine Berlin,CNIC,LIFE TECHNOLOGIES GmbH,UOXF,MPG,AMCFunder: European Commission Project Code: 289600more_vert Open Access Mandate for Publications and Research data assignment_turned_in Project2021 - 2025Partners:UNIBO, LIFE TECHNOLOGIES GmbH, FUNDACIO CENTRE DE REGULACIO GENOMICA, i-HD, DH HEALTHCARE PROVIDER SOFTWARE SPAIN SLU +21 partnersUNIBO,LIFE TECHNOLOGIES GmbH,FUNDACIO CENTRE DE REGULACIO GENOMICA,i-HD,DH HEALTHCARE PROVIDER SOFTWARE SPAIN SLU,AUSTRALO INTERINNOV MARKETING LAB SL,MLL,Leipzig University,UPM,CCIP,UCPH,AP-HP,UMC,DXC Technology,CING,GERENCIA REGIONAL DE SALUD DE CASTILLA Y LEON,UNIPD,UoA,Cineca,UNIVERSITE GUSTAVE EIFFEL,CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO,HUMANITAS MIRASOLE SPA,VHIR,DW,FOUNDATION FOR RESEARCH AND TECHNOLOGYHELLAS,UNITOFunder: European Commission Project Code: 101017549Overall Budget: 9,999,060 EURFunder Contribution: 9,999,060 EURGENOMED4ALL will support the pooling of genomic, clinical data and other “-omics” health data (data EHR, PET, MRI and CT , Next Generation Sequencing, Microarray, Genome Wide Association, Copy Number Variations, DNA sequencing, RNA sequencing, including single cell, etc.) through a secure and privacy respectful data sharing platform based on the novel Federated Learning scheme, to advance research in personalised medicine in haematological diseases thanks to advanced novel AI models and standardized sharing of cross-border data. GENOMED4ALL will make use of the existing infrastructures and initiatives, including powerful High Performance Computing facilities, hospital registries, data processing tools, and pre-existing repositories, starting from 10 clinical partners repositories to be enlarged especially by the resources provided by ERN-EuroBloodNet where GENOMED4ALL clinical partners have a leading position, which contain 66 relevant clinical sites providing repositories and knowledge, for the successful exploitation of genomics, clinical and other related “-omics” data to facilitate personalised medicine in common, rare and ultrarare haematological diseases to demonstrate the versatility and utility of the solutions, and 20 external of this network. GENOMED4ALL will demonstrate the potential and benefits of trustable and explainable AI technologies, with a novel approach to AI models and algorithms using AI advanced deep learning, variational autoencoders, generative models, besides combining with advanced statistical and Machine learning processes approaches to exploit the powerful set of “-omics” data which will be at researchers’ disposal. This will allow for identifying new knowledge, to support clinical research and decision making by linking Europe's relevant genomic repositories in haematological diseases, while ensuring full compliance with data protection legislation and ethical principles, and increasing the AI trust for personalized medicine.
more_vert
